Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Mullally, Ann  [Clear All Filters]
2014
Chen E, Schneider RK, Breyfogle LJ, Rosen EA, Poveromo L, Elf S, Ko A, Brumme K, Levine R, Ebert BL, et al. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice combine to promote disease progression in myeloproliferative neoplasms. Blood. 2014.
Chen E, Mullally A. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?. Hematology Am Soc Hematol Educ Program. 2014;2014(1):268-276.
2018
Schneider RK, Mullally A, Dugourd A, Peisker F, Hoogenboezem R, Van Strien PMH, Bindels EM, Heckl D, Büsche G, Fleck D, et al. Gli1 Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. Cell Stem Cell. 2018;23(2):308-309.
2021
Takei H, Coelho-Silva JLuiz, Leal CTavares, Rocha AQueiroz Ar, Bianco TMantello, Welner RS, Mishima Y, Kobayashi IS, Mullally A, Lima K, et al. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. Cancer Sci. 2021.
2022
How J, Garcia JS, Mullally A. Biology and therapeutic targeting of molecular mechanisms in MPN. Blood. 2022.
Jutzi JS, Marneth AE, Jiménez-Santos MJosé, Hem J, Guerra-Moreno A, Rolles B, Bhatt S, Myers SA, Carr SA, Hong Y, et al. CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response. Leukemia. 2022.